HOME >> MEDICINE >> NEWS
Hyperhidrosis and its treatment becoming better understood

ROCHESTER, Minn. -- The often embarrassing, excessive sweating disorder, hyperhidrosis, and its treatment options are gaining greater attention from physicians. This is improving the efficacy of treatment and minimizing its adverse effects, Mayo Clinic authors write in the May issue of Mayo Clinic Proceedings.

Hyperhidrosis is one of the oldest known dermatologic conditions that even today is misconceived as rare and untreatable, says John Eisenach, M.D., a Mayo Clinic anesthesiologist and the primary author of the clinical review.

"Both ancient and modern medicine have been perplexed by this entity," says Dr. Eisenach.

The description and definition of excessive sweating date back to Hippocrates in the 4th century B.C. Today, the diagnosis and treatment of severe cases command a stepwise, multidisciplinary approach from the primary care physician, the dermatologist, the neurologist, and the surgeon. Variables include the site affected, the degree of severity and the response to treatment.

Dr. Eisenach and colleagues outline their findings on the evolving therapies and how this disorder is not as rare as commonly thought. "I think we've all shaken hands with someone who is affected by this," he says. "I just hope people with this condition seek help, because of the emerging treatment options and high satisfaction rates that can be obtained, even in severe cases."

The Food and Drug Administration approval of botulinum toxin type A (Botox) has provided an effective treatment of excessive sweating, particularly for the underarms. Other treatments may be utilized for excessive sweating on the face, the palms, or soles of the feet. A recent survey suggests that the prevalence of primary hyperhidrosis is 2.8 percent in the U.S. population, 1.4 percent have excessive sweating in the underarms (axillary hyperhidrosis), and one-sixth are projected to have sweating that is intolerable or interferes with daily activities. There also is a
'"/>


11-May-2005


Page: 1 2 3

Related medicine news :

1. Spot on treatment for acne
2. New treatment boosts muscle function in myasthenia gravis
3. New treatment effective in counteracting cocaine-induced symptoms
4. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
5. Preventive treatments in elderly people needs rethinking
6. Osteoporosis screening and treatment may be cost-effective for selected older men
7. Quality of treatment guidelines
8. Green tea holds promise as new treatment for inflammatory skin diseases
9. Many heart attack patients still not getting emergency clot-busting treatment
10. Electric fields have potential as a cancer treatment
11. New algorithm matches any tumor cells to best possible anti-cancer treatments

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Hyperhidrosis and its treatment becoming better understood

(Date:6/19/2013)... Salt Lake City, UT (PRWEB) June 19, 2013 ... wellness companies : , In July 2013, Orriant ... optimize their participation rates, and maintain compliance with ... implemented allowing employees to receive wellness incentives if ... Orriant has announced they have been compliant with ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 As ... cancer continue to mount in courts throughout the U.S., ... Drug Administration (FDA) recently held a meeting to discuss ... as incretin mimetics. According to a June 12th ... from the makers of Januvia and similar drugs, following ...
(Date:6/19/2013)... In what is believed to be the largest follow-up ... hereditary dystonia a movement disorder that can cause ... report good success rates and lasting benefits. , Michele ... at Cedars-Sinai Medical Center,s Department of Neurology, and Ron ... at Beth Israel Deaconess Medical Center in Boston, published ...
(Date:6/19/2013)... disparities between minority and white clients in success ... these disparities vary widely from state to state. ... states there,s something amiss," says Stephan Arndt, Ph.D., ... strong racial and ethnic disparities for people in ... successfully, and those disparities are something we need ...
(Date:6/19/2013)... The Movement Disorders Center ... urologists with specialists in physical therapy, occupational therapy ... and their family members to manage diseases and ... also have the opportunity to participate in the ... disorders can be relentlessly progressive and disabling conditions, ...
Breaking Medicine News(10 mins):Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2
(Date:6/19/2013)... MUMBAI, India , June 19, ... Book Bureau has recently added DrugPatentWatch ... Databases. ( http://www.bharatbook.com/drugpatentwatch-tour.pdf ) ... DrugPatentWatch provides comprehensive information on pharmaceutical, ... value-added information supports the critical business ...
(Date:6/19/2013)... --  Nektar Therapeutics (Nasdaq: NKTR ) today ... study for NKTR-181, a first-in-class, opioid analgesic molecule ... slow rate of entry is designed to reduce the euphoria ... current opioid analgesics. 1 In the study data being ... in "drug liking" and "feeling high" scores and had highly ...
(Date:6/19/2013)... June 19, 2013 BD Biosciences, a segment of ... a leading global medical technology company, today announced the launch ... latest in its line of high-performance research flow cytometers. ... multicolor analysis with the most compact footprint in its class ... a height of 30" (76.2 cm). Recognizing that space is ...
Breaking Medicine Technology:Drug Patent Watch 2Drug Patent Watch 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2
Cached News: